Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer

Abstract

BackgroundOvarian cancer is the leading cause of gynecologic cancer death in the United States despite effective first-line systemic chemotherapy. Cancer stem cells (CSCs) retain the ability to self-renew and proliferate and may be a means of harboring disease that evades standard treatment strategies. We previously performed a high-throughput screen to assess differential protein expression in ovarian CSCs compared to non-CSCs and observed that Thy-1 was more highly expressed in CSCs. Our primary aim was to validate Thy-1 (CD90) as a cancer stem cell (CSC) marker in epithelial ovarian cancer (EOC), correlate with clinical outcomes, and assess as a potential therapeutic target.ResultsKaplan Meier (KM) Plotter data were correlated with survival outcomes. Quantitative real-time PCR, flow cytometry, and immunoblots assessed RNA and protein expression. Limiting dilution assays assessed self-renewal capacity and proliferation assays assessed proliferative capacity. RNA in-situ hybridization was performed on patient specimens to assess feasibility. Thy-1 (CD90) is more highly expressed in ovarian CSCs than non-CSCs, in EOC compared to benign ovarian epithelium (P < 0.001), and is highest in serous EOC (P < 0.05). Serous ovarian cancers with high Thy-1 expression have poorer outcomes (median PFS 15.8 vs. 18.3 months, P = 0 < 0.001; median OS 40.1 v. 45.8 months, P = 0.036). Endometrioid ovarian cancers with high Thy-1 have poorer PFS, but no difference in OS (upper quartile PFS 34 v. 11 months, P = 0.013; quartile OS not reached, P = 0.69). In vitro, Thy-1 expression is higher in CSCs versus non-CSCs. EOC cells with high Thy-1 expression demonstrate increased proliferation and self-renewal. Thy-1 knockdown in EOC cells decreases proliferative capacity and self-renewal capacity, and knockdown is associated with decreased expression of stem cell transcription factors NANOG and SOX2. RNA in situ hybridization is feasible in ovarian cancer tissue specimens.ConclusionsThy-1 is a marker of ovarian CSCs. Increased expression of Thy-1 in EOC predicts poor prognosis and is associated with increased proliferative and self-renewal capacity. Thy-1 knockdown decreases proliferative and self-renewal capacity, and represents a potential therapeutic target.

CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype

“…The latest findings report that in several tumors, including ovarian cancer, THY1 is overexpressed in cancer stem cells (CSC) and the tumor microenvironment, enhancing proliferation and metastasis abilities [ 7 ]. Furthermore, in HCC, THY1 expression is related to poor tumor differentiation, invasive properties, and dismal prognosis [ 8 , 9 ].…”

A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer

“…Numerous genes associated with stemness have been reported to be characteristic of OCSCs [ 30 , 31 ]. It was observed that 974 significantly decreased the expression of the well-known stemness genes Bmi-1, Nanog, Oct4, and Sox2 in OVCAR3 ( Figure 2 C) and OVCAR5 cells ( Figure 2 D).…”

A Novel Six-Gene Signature for Prognosis Prediction in Ovarian Cancer

“…THY1 is more highly expressed in ovarian CSCs than in non-CSCs, and high THY1 expression in patients with serous OC indicates poorer outcomes. THY1 promotes proliferation and self-renewal in OC (Elizabeth et al, 2019). BGN was indicated to be an endogenous inhibitor of bladder cancer cell proliferation by antiproliferative tyrosine kinase inhibitors.…”